225 related articles for article (PubMed ID: 30287814)
1. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.
Moulopoulos LA; Koutoulidis V; Hillengass J; Zamagni E; Aquerreta JD; Roche CL; Lentzsch S; Moreau P; Cavo M; Miguel JS; Dimopoulos MA; Rajkumar SV; Durie BGM; Terpos E; Delorme S
Blood Cancer J; 2018 Oct; 8(10):95. PubMed ID: 30287814
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).
Gleeson TG; Moriarty J; Shortt CP; Gleeson JP; Fitzpatrick P; Byrne B; McHugh J; O'Connell M; O'Gorman P; Eustace SJ
Skeletal Radiol; 2009 Mar; 38(3):225-36. PubMed ID: 19009290
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of computed tomography and diffusion-weighted imaging as first-line imaging modality according to the International Myeloma Working Group (IMWG) imaging algorithm for monoclonal plasma cell disorders.
Yoon MA; Chee CG; Chung HW; Lee DH; Kim KW
Acta Radiol; 2022 May; 63(5):672-683. PubMed ID: 33853375
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM).
Ippolito D; Besostri V; Bonaffini PA; Rossini F; Di Lelio A; Sironi S
Eur J Radiol; 2013 Dec; 82(12):2322-7. PubMed ID: 24074647
[TBL] [Abstract][Full Text] [Related]
5. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
[TBL] [Abstract][Full Text] [Related]
6. Multiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging.
Mosebach J; Thierjung H; Schlemmer HP; Delorme S
Rofo; 2019 Nov; 191(11):998-1009. PubMed ID: 31137045
[TBL] [Abstract][Full Text] [Related]
7. Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM).
Zacchino M; Bonaffini PA; Corso A; Minetti V; Nasatti A; Tinelli C; Dore R; Calliada F; Sironi S
Eur Radiol; 2015 Nov; 25(11):3382-9. PubMed ID: 25987427
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma.
Gundesen MT; Asmussen JT; Haukås E; Schubert M; Abildgaard N; Schjesvold F; Lund T
Eur J Haematol; 2022 May; 108(5):423-429. PubMed ID: 35113466
[TBL] [Abstract][Full Text] [Related]
9. Organ dose and total effective dose of whole-body CT in multiple myeloma patients.
Hemke R; Yang K; Husseini J; Bredella MA; Simeone FJ
Skeletal Radiol; 2020 Apr; 49(4):549-554. PubMed ID: 31612246
[TBL] [Abstract][Full Text] [Related]
10. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease.
Pianko MJ; Terpos E; Roodman GD; Divgi CR; Zweegman S; Hillengass J; Lentzsch S
Clin Cancer Res; 2014 Dec; 20(23):5888-97. PubMed ID: 25294899
[TBL] [Abstract][Full Text] [Related]
11. Role of
Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
[TBL] [Abstract][Full Text] [Related]
12. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
[TBL] [Abstract][Full Text] [Related]
13. Implemented myeloma management with whole-body low-dose CT scan: a real life experience.
Mangiacavalli S; Pezzatti S; Rossini F; Doni E; Cocito F; Bolis S; Corso A
Leuk Lymphoma; 2016 Jul; 57(7):1539-45. PubMed ID: 26788613
[TBL] [Abstract][Full Text] [Related]
14. Whole-body low-dose computed tomography (WBLDCT) in staging and re-staging of multiple myeloma.
Ippolito D; Giandola T; Maino C; Pecorelli A; Ragusi M; Porta M; Gandola D; Franzesi CT; Sironi S
Ann Hematol; 2021 May; 100(5):1241-1249. PubMed ID: 33660034
[TBL] [Abstract][Full Text] [Related]
15. Imaging in multiple myeloma: How? When?
Zamagni E; Tacchetti P; Cavo M
Blood; 2019 Feb; 133(7):644-651. PubMed ID: 30587527
[TBL] [Abstract][Full Text] [Related]
16. Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria.
Ormond Filho AG; Carneiro BC; Pastore D; Silva IP; Yamashita SR; Consolo FD; Hungria VTM; Sandes AF; Rizzatti EG; Nico MAC
Radiographics; 2019; 39(4):1077-1097. PubMed ID: 31283452
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma.
Ippolito D; Talei Franzesi C; Spiga S; Besostri V; Pezzati S; Rossini F; Sironi S
Br J Haematol; 2017 May; 177(3):395-403. PubMed ID: 28233900
[TBL] [Abstract][Full Text] [Related]
18. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
19. Updates and Ongoing Challenges in Imaging of Multiple Myeloma:
Wu F; Bernard S; Fayad LM; Ilaslan H; Messiou C; Moulopoulos LA; Mulligan ME
AJR Am J Roentgenol; 2021 Oct; 217(4):775-785. PubMed ID: 33978464
[TBL] [Abstract][Full Text] [Related]
20. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
